Sanofi, Re­gen­eron say Dupix­ent suc­ceeds in an­oth­er late-stage COPD study, set­ting up fil­ing for FDA ap­proval

The megablock­buster an­ti-in­flam­ma­to­ry drug Dupix­ent suc­ceed­ed in a sec­ond late-stage COPD tri­al, Sanofi and Re­gen­eron said Mon­day, as the two drug­mak­ers plan to file for …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER